IMPORTANCE Phosphodiesterase-5 inhibition with sildenafil compared with a placebo had no effect on the exercise capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction (RELAX) clinical trial. Metabolic impairments may explain the neutral results.
H eart failure with preserved ejection fraction (HFpEF) is a complex syndrome associated with many diagnostic and therapeutic challenges. 1 A recent clinical trial, Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX), 2 did not demonstrate improvements in exercise capacity or clinical status of patients with HFpEF who were treated with sildenafil compared with participants treated with a placebo. In this study, we performed quantitative, targeted metabolomic profiling in RELAX samples to examine the underlying mechanisms modified by sildenafil that could have mediated the neutral trial results and to identify biomarkers associated with clinical outcomes.
Methods

Study Cohort
The RELAX trial 2 was a multicenter, double-blind trial conducted through the Heart Failure Clinical Research Network from 2008 to 2012 on outpatients with HFpEF who were randomized to be treated with a placebo (n = 103) or with sildenafil (n = 113) for 24 weeks. The study was approved by the institutional review board at all participating sites, and all participants provided informed written consent. The primary trial end point was a change in peak oxygen consumption (change in oxygen consumption = 24-week−baseline oxygen consumption). Secondary end points included changes in 6-minute walk distance, a composite clinical rank score (based on time to death and cardiovascular or cardiorenal hospitalization), and clinical biomarkers (creatinine, cystatin C, N-terminal pro-B-type natriuretic peptide, and endothelin-1). The current biomarker substudy had 160 paired plasma samples available (79 samples from patients treated with sildenafil, 81 samples from patients treated with a placebo).
Metabolomic Profiling
Plasma metabolomic profiling (45 acylcarnitines, 15 amino acids, 5 conventional) was conducted using tandem flow injection mass spectrometry (Acquity TOD Triple Quadrupole; Waters) with stable-isotope-labeled internal standards 3 and by conventional means 3 (eMethods and eTable 1 in the Supplement).
Statistical Analyses
Baseline patient characteristics and metabolite levels between treatment groups were compared using the Wilcoxon rank sum test (continuous variables) and the χ 2 /Fisher exact test (categorical variables). An exploratory analysis of changes in metabolite levels was first performed using the Wilcoxon signed rank test, stratified by treatment received. A linear regression model was then used with changes in metabolite regressed on treatment received and adjusted for age, race/ ethnicity, sex, baseline metabolite level, and creatinine. Correlations between changes in metabolite levels and clinical biomarkers were assessed (Spearman coefficient) for the full cohort and by treatment received. Baseline metabolite levels were assessed for association with the change in oxygen consumption, the change in 6-minute walk distance, and the composite clinical score using multivariable linear regression adjusted for age, sex, race/ethnicity, smoking status, the New York Heart Association class, and the treatment received. Sensitivity analyses adjusted for baseline creatinine levels were also performed. A 2-tailed α of .05 was used for statistical significance, and the false discovery rate controlling procedure was used to adjust for testing multiple hypotheses 4 for paired analyses. The analyses of clinical outcomes and correlations were unadjusted for multiple comparisons. All statistical analyses were conducted using R, version 3.2 (The R Foundation).
Results
Baseline clinical characteristics and metabolite profiles did not differ significantly between treatment groups, except for a lower prevalence of hypertension among the group treated with sildenafil, which was similar to results of the full trial 2 ( Table 1, eTable 2 in the Supplement).
No metabolites changed significantly with treatment with a placebo (eTable 3 in the Supplement). The levels of 7 metabolites changed significantly with sildenafil treatment (false discovery rate-adjusted): alanine, proline, and lactate decreased; and 3 short-chain dicarboxylacylcarnitines (SCDAs) (glutaryl carnitine, octenedioyl carnitine, and adipoyl carnitine) and 1 long-chain acylcarnitine (LCAC), palmitoyl carnitine, increased ( Table 2) . Consistent with the full trial, 2 our analysis also showed an association between increased clinical biomarkers creatinine, cystatin C, and endothelin-1 and sildenafil treatment (Table 2 ). In the multivariable regression adjusted for age, sex, race/ethnicity, and baseline metabolite level and creatinine, alanine and proline changes were negatively associated with treatment, while changes in SCDA and LCAC levels were positively associated (eTable 4 in the Supplement). Correlations between changes in metabolites and clinical biomarkers were most significant between alanine and
Key Points
Question What are the underlying mechanisms and biomarkers associated with sildenafil treatment in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction (RELAX) trial, which compared sildenafil with a placebo for treating patients with heart failure with preserved ejection fraction?
Findings In this metabolomic profiling study using samples from the RELAX trial, levels of circulating amino acids, short-chain dicarboxylacylcarnitines, and long-chain acylcarnitines increased significantly with sildenafil but not with a placebo among patients with heart failure with preserved ejection fraction. Higher baseline levels of short-chain dicarboxylacylcarnitine metabolite 3-hydroxyisovalerylcarnitine/malonylcarnitine and asparagine/aspartic acid were associated with worse clinical rank scores in groups treated with sildenafil and a placebo.
Meaning Circulating metabolites may contribute to the underlying mechanisms associated with sildenafil and serve as biomarkers for outcomes in heart failure with preserved ejection fraction. ); SCDA levels (glutaryl carnitine, methylmalonyl carnitine/succinyl carnitine, 3-hydroxyisovalerylcartine/ malonylcarnitine, octenedioyl carnitine, 3-hydroxy-cis-5-octenoyl carnitine) and creatinine/cystatin C, and LCACs and endothelin-1 (eFigure and eTable 5 in the Supplement).
Similar to the full trial, our analyses did not reveal any difference in the primary (the change in oxygen consumption) or secondary end points (the change in 6-minute walk distance and composite clinical score) between treatment groups (P = .80, .98, and .75, respectively). Higher levels of 7 baseline metabolites were associated with worse clinical scores: SCDA 3-hydroxyisovalerylcartine/malonyl carnitine, methylmalonyl carnitine/succinyl carnitine, and glutaryl carnitine (β, −96.60, −50.24, and −31.35, respectively; P = .001, .02, and .03, respectively); short-chain acylcarnitines butyryl carnitine/ isobutyryl carnitineand tigyl carnitine (β, −5.60 and −85.59; P = .02); and amino acids asparagine/aspartic acid and citrulline (β, −0.02 and −0.08; P = .01 and .03, respectively) ( Table 3) . After adjusting for baseline creatinine, asparagine/aspartic acid remained significantly associated with the clinical score (P = .02), while 3-hydroxyisovalerylcartine/malonylcarnitine showed a trend toward association (P = .09).
Discussion
Using targeted metabolomic profiling in paired samples from the RELAX trial, we found circulating metabolites among patients with HFpEF that were modified by treatment with sildenafil: decreased alanine and proline, and increased LCACs and SCDAs. The increases in LCAC and SCDA metabolites correlated with worsening collagen metabolism biomarkers (endothelin-1) and renal function (creatinine and cystatin C) biomarkers, respectively. Additionally, baseline levels of the SCDA metabolite 3-hydroxyisovalerylcartine/malonylcarnitine and asparagine/aspartic acid were associated with a worse composite clinical rank score at 24 weeks.
Long-chain acylcarnitine metabolites have been implicated in mitochondria-mediated inflammation and cellular stress promotion. In this study, LCAC metabolite levels increased with sildenafil treatment and exhibited a significant correlation with endothelin-1, an established prognostic biomarker for mortality and morbidity in heart failure. 5 While the exact mechanism of sildenafil-associated elevation in LCAC metabolites is unclear, our findings suggest that the role of mitochondrial dysfunction and alterations in the endothelin-1 signaling pathway are potential explanations. The accumulation of SCDA metabolites reports on dysregulated endoplasmic reticulum stress of the ubiquitinproteasome system, which induces an autophagy to remove damaged cells. 6, 7 In this study, increased SCDAs by sildenafil treatment may be explained by this pathway activating, which could lead to a disrupted cellular homeostasis, dysregulated autophagy, and worse long-term outcomes. This negative consequence may have contributed to the lack of benefits received by those treated with sildenafil therapy. In this study, higher baseline levels of the SCDA 3-hydroxyisovalerylcartine/malonylcarnitine and amino acids asparagine/aspartic acid were associated with worse clinical scores. The SCDA result is consistent with previous studies that demonstrated an association between SCDA metabolites and cardiovascular events. 8, 9 Notably, this association was attenuated after adjusting for baseline renal function, which could be because of an impaired clearance of SCDAs with impaired renal function or an underlying pathophysiology affecting renal function and SCDA metabolism concordantly. In prior studies, SCDAs were associated with incident cardiovascular events even after adjusting for baseline estimated glomerular filtration rates, 10 suggesting that a complex relationship exists between SCDAs, renal function, and cardiovascular disease. The amino acid result is consistent with recent studies showing higher levels of asparagine/aspartic acid in HFpEF compared with patients who had not experienced heart failure, 11 highlighting the importance of underlying alterations in amino acid metabolism in HFpEF. The internal standards used to quantify asparagine/aspartic acid do not discriminate these 2 metabolites, and thus we were unable to determine the specific biologic pathway represented.
Limitations
This study has several limitations. Patients were selected who could perform the peak oxygen consumption test, which may have introduced biases. Additionally, our results of metabolite association with clinical end points were attenuated when adjusting for baseline renal function, suggesting that a complex relationship exists between SCDAs, renal function, and cardiovascular disease.
Conclusions
Among patients with HFpEF, phosphodiesterase type 5 inhibition with sildenafil treatment resulted in significantly increased LCAC and SCDA metabolites that paralleled increases in adverse clinical markers. These results suggest that there is a potential role of mitochondrial dysfunction and endoplasmic reticulum stress among patients with HFpEF who are treated with sildenafil and provide potential candidates for biomarkers associated with clinical outcomes. Author Contributions: Drs Wang and Shah had full access to all the data in the study and take Abbreviation: FDR, false discovery rate.
a Metabolite abbreviations are included in eTable 1 in the Supplement.
b P value from Wilcoxon signed-rank tests. 
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eMethods
Quantitative metabolomic profiling was performed using methods previously described [1] [2] [3] . Specifically, frozen plasma samples in100 µL aliquots were thawed and first protein precipitated with methanol. Following precipitation, the supernatants were dried and esterified with hot acidic methanol (acylcarnitines) or n-butanol (amino acids). Metabolite assays were performed using tandom flow injection mass spectrometry (MS) with a Quattro Micro instrument (Waters Corpoeration, Milford, MA). Metabolite quantification was achieved by the addition of stable isotope labeled internal standards. Assay detection ranges are 0.05-40 mM (acylcarnitines) and 5-1000 mM (amino acids). Targeted metabolite levels below the lower limits of quantification were reported and analyzed as "0". Two acylcarnitines (C6 and C7-DC) with > 25% of values 0 were excluded from further analysis.
Five additional metabolites (nonesterified fatty acids [NEFA], total ketones, lactate, beta-hydroxybutyrate and glucose) were quantified on a Beckman-Coulter DxC600 clinical chemistry analyzer using previously described methods 2 . The reagents used were obtained from Wako (Richmond, VA 
